Purpose This study aimed to explore the molecular pathogenesis of Graves’ disease (GD). Methods The gene expression profile in CD4 + T cells from GD patients and healthy controls were analyzed through mRNA-sequencing. The expression of NR4A2 was determined by quantitative real-time PCR and western blot. The levels of Th17 and Treg were determined by flow cytometry. ELISA was employed to detect the levels of IL-10, IL-17A, IL-17F and IL-22. Results In the CD4 + T cells from GD patients, there were 128 up-regulated and 510 down-regulated genes. Subsequently, we focused on the role of nuclear receptor 4 group A member 2 (NR4A2) in GD. NR4A2 was lowly expressed in the CD4 + T cells from GD patients. Its expression was negatively correlated with free triiodothyronine and tetraiodothyronine, but positively correlated with thyroid stimulating hormone. NR4A2 knockdown decreased the percentage of Treg cells, with a decreased IL-10 level. While its over-expression augmented the Treg differentiation, with an elevated IL-10 level. In addition, knockdown or over-expression of NR4A2 showed no significant influence on Th17 differentiation. Conclusion These results indicate that the low level of NR4A2 in GD patients may suppress Treg differentiation, but have no influence on Th17 differentiation, leading to the imbalance of Th17/Treg and contributing to the development of GD. Revealing the role of NR4A2 in GD provides a novel insight for the treatment of GD.
Home>A role of NR4A2 in Graves’ disease: regulation of Th17/Treg
A role of NR4A2 in Graves’ disease: regulation of Th17/Treg
- Impact factors: 3.7
- Publication: ENDOCRINE
- Author:Zhao Shuiying, Wang Xinyu, Huang Fengjiao, Zhou Yingying, Meng Dongdong, Zhao Di, Wang Jiao, Zhang Haohao, Wu Lina, Zhang Ying, Zhao Lin, Zhang Lixia, Song Yi, Wang Qingzhu
- DOI citation-doi:10.1007/s12020-023-03490-9
- Date:2023-08-31